Review: heterogeneous glioma-associated senescence and therapy resistance
This review rethinks glioma-associated senescence as a dynamic, context-dependent state with phenotypic, functional, spatial and temporal heterogeneity that may drive tumor survival and resistance to conventional glioma therapies. [1]
Automatic summary · not editorially reviewed
The key findings
The review describes glioma-associated senescence as a dynamic, context-dependent state rather than a uniform endpoint, divided into therapy-induced and spontaneous senescence. [1]
The authors state that heterogeneity of glioma-associated senescence is a key driver of intratumoral complexity, adaptive tumor survival and resistance to conventional glioma therapies. [1]
The review outlines emerging senescence-targeted strategies such as senolytics and senomorphics and combination regimens, and highlights challenges in translating them into clinical practice. [1]
The source at a glance
- Study type / format
- Narrative review (abstract only)
- Population / context
- Malignant gliomas, particularly glioblastoma (WHO grade IV), as discussed in a review
- Summary based on
- Study abstract
- Original publication
- August 3, 2026
Senescence as a heterogeneous state in glioblastoma
The review describes cellular senescence as traditionally a stress-induced, irreversible cell-cycle arrest with tumor-suppressive functions in normal somatic cells. In malignant gliomas, especially glioblastoma (WHO grade IV), it appears remarkably heterogeneous. The authors frame glioma-associated senescence as a dynamic, context-dependent cellular state rather than a uniform endpoint, and divide it by induction mechanism into therapy-induced senescence (TIS) and spontaneous senescence (SS).
Supporting source [1]
Drivers and secretory crosstalk in the tumor microenvironment
According to the review, the heterogeneity of glioma-associated senescence is a key driver of intratumoral complexity, adaptive tumor survival and resistance to conventional glioma therapies, and it engages in bidirectional crosstalk with the brain tumor microenvironment. The authors list molecular drivers: alterations in core cell-cycle regulatory pathways, dysregulation of oncogenic signaling including EGFR, PI3K-AKT and MAPK pathways, epigenetic modifications, metabolic reprogramming and regulation by the tumor microenvironment. They also discuss the senescence-associated secretory phenotype (SASP) as a core functional feature of senescent or senescence-like glioma cells, its compositional and functional heterogeneity, and its role in remodeling the glioma microenvironment and mediating non-cell-autonomous effects in therapy resistance.
Supporting source [1]
Dual role of therapy-induced senescence and proposed strategies
The review analyzes the dual role of TIS in glioma treatment and mechanisms by which TIS-associated senescence-like states may contribute to tumor recurrence. It outlines emerging senescence-targeted therapeutic strategies, including senolytics and senomorphics, and optimized combination regimens with conventional therapies. The authors present these as emerging strategies and highlight challenges and future perspectives in translating them into clinical practice; the abstract reports no trial results.
Supporting source [1]
How to interpret this
This is an abstract of a review; the full text was not reviewed. The abstract reports no primary data, sample sizes, follow-up or trial results, and the proposed therapeutic strategies are described as emerging rather than established.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Yan Y, Zhang B, Chen S, Sun Y, Huang J, Li G. · europepmc.org · August 3, 2026